Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
Dlouhy I, Karube K, Enjuanes A, Salaverria I, Nadeu F, Ramis-Zaldivar JE, Valero JG, Rivas-Delgado A, Magnano L, Martin-García D, Pérez-Galán P, Clot G, Rovira J, Jares P, Balagué O, Giné E, Mozas P, Briones J, Sancho JM, Salar A, Mercadal S, Alcoceba M, Valera A, Campo E, López-Guillermo A. Dlouhy I, et al. Br J Haematol. 2022 Feb;196(3):589-598. doi: 10.1111/bjh.17858. Epub 2021 Oct 10. Br J Haematol. 2022. PMID: 34632572
Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy.
Rovira J, Valera A, Colomo L, Setoain X, Rodríguez S, Martínez-Trillos A, Giné E, Dlouhy I, Magnano L, Gaya A, Martínez D, Martínez A, Campo E, López-Guillermo A. Rovira J, et al. Among authors: dlouhy i. Ann Hematol. 2015 May;94(5):803-12. doi: 10.1007/s00277-014-2271-1. Epub 2014 Dec 14. Ann Hematol. 2015. PMID: 25501975 Free PMC article.
MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.
Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L, Martínez-Trillos A, Giné E, Dlouhy I, Magnano L, Delgado J, Martínez A, Villamor N, Campo E, López-Guillermo A. Rovira J, et al. Among authors: dlouhy i. Clin Cancer Res. 2016 Jun 1;22(11):2755-64. doi: 10.1158/1078-0432.CCR-15-1525. Epub 2016 Jan 20. Clin Cancer Res. 2016. PMID: 26792260
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Martín A, Redondo AM, Dlouhy I, Salar A, González-Barca E, Canales M, Montes-Moreno S, Ocio EM, López-Guillermo A, Caballero D; Spanish Group for Lymphomas and Autologous Bone Marrow (GELTAMO). Martín A, et al. Among authors: dlouhy i. Br J Haematol. 2016 Apr;173(2):245-52. doi: 10.1111/bjh.13945. Epub 2016 Feb 5. Br J Haematol. 2016. PMID: 26847165 Free article. Clinical Trial.
Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression.
Valera A, Epistolio S, Colomo L, Riva A, Balagué O, Dlouhy I, Tzankov A, Bühler M, Haralambieva E, Campo E, Soldini D, Mazzucchelli L, Martin V. Valera A, et al. Among authors: dlouhy i. Mod Pathol. 2016 Aug;29(8):844-53. doi: 10.1038/modpathol.2016.71. Epub 2016 Apr 29. Mod Pathol. 2016. PMID: 27125356 Free article.
Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2 -microglobulin yields a more accurate GELTAMO-IPI.
Montalbán C, Díaz-López A, Dlouhy I, Rovira J, Lopez-Guillermo A, Alonso S, Martín A, Sancho JM, García O, Sánchez JM, Rodríguez M, Novelli S, Salar A, Gutiérrez A, Rodríguez-Salazar MJ, Bastos M, Domínguez JF, Fernández R, Gonzalez de Villambrosia S, Queizan JA, Córdoba R, de Oña R, López-Hernandez A, Freue JM, Garrote H, López L, Martin-Moreno AM, Rodriguez J, Abraira V, García JF; GELTAMO-IPI Project Investigators. Montalbán C, et al. Among authors: dlouhy i. Br J Haematol. 2017 Mar;176(6):918-928. doi: 10.1111/bjh.14489. Epub 2017 Jan 20. Br J Haematol. 2017. PMID: 28106247 Free article.
LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
Colomo L, Vazquez I, Papaleo N, Espinet B, Ferrer A, Franco C, Comerma L, Hernandez S, Calvo X, Salar A, Climent F, Mate JL, Forcada P, Mozos A, Nonell L, Martinez A, Carrio A, Costa D, Dlouhy I, Salaverria I, Martin-Subero JI, Lopez-Guillermo A, Valera A, Campo E; Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB). Colomo L, et al. Among authors: dlouhy i. Am J Surg Pathol. 2017 Jul;41(7):877-886. doi: 10.1097/PAS.0000000000000839. Am J Surg Pathol. 2017. PMID: 28288039
54 results